3 Penny Stocks with Multibagger Potential for the Second Half of 2023

Stocks to buy

With investors looking for growth wherever they can find it, it’s a good time to look at penny stocks to watch in 2023. Granted, penny stocks carry a higher risk than blue-chip stocks, but they also carry the potential for outsized returns. These stocks can move quickly on little to no news. And to be fair, that price action is all many traders care about.  On the other hand, if you’re looking for penny stocks that may not only be a good trade today but a solid investment that you can hold over several months, you have to look beyond the headlines. That’s what analysts are paid to do. Investors can look at analyst ratings to find companies with business models that have the potential to make them multi-bagger penny stocks.  

Investors may have to hold onto these stocks a little longer than a typical trade, but if you have that patience and a high-risk tolerance, here are three penny stocks to watch in 2023.  

Bionano Genomics (BNGO) 

Page of newspaper with words penny stocks. high return penny stocks

Source: Vitalii Vodolazskyi / Shutterstock.com

Gene editing will be a closely watched sector for the next decade. So it makes sense that Bionano Genomics (NASDAQ:BNGO) kicks off this list of penny stocks to watch in 2023. The company has several lines of business. However, its signature product is its Saphyr system which is an automated platform that optically maps genomes of ultra-high molecular weight DNA.  

The company reported an installed base of 240 units at the end of 2022. That was a 46% increase from the prior year. The company is also forecasting 45% growth in that base in 2023. The concern seems to be that the company is not growing its revenue as fast as analysts would like to see. This is a competitive market with an $8 billion valuation. Nevertheless, BNGO stock has a consensus Buy rating with a 700% potential upside.  

And although institutional investors aren’t heavily invested in the stock, there have been three insider buys since mid-May. 2023. If you believe in the adage that there are many reasons that insiders sell a stock, but only one reason they buy, that’s something to take note of as we head into the second half of 2023.  

Nauticus Robotics (KITT) 

Pennies in a jar on top of a background of blurred pennies. Penny stocks.

Source: John Brueske / Shutterstock

Artificial intelligence may be an unsustainable bubble propping up the market. It may also be a long-term driver of future growth. Both statements can be true. The trick is to figure out which companies are here for the long haul. Nauticus Robotics (NASDAQ:KITT) appears to be one of those companies.  

The company combines AI with robotics in a series of products that are focusing on areas such as sustainable subsea technology. In June, the company announced a contract with Petrobras to develop and test the company’s AUV (autonomous underwater vehicle) Aquanaut in Brazil. According to company data, the ocean economy is a $2.5 trillion market. The company’s products may be instrumental in helping develop offshore wind projects as well as mining for rare earth minerals. 

KITT stock has only been trading publicly since 2021, and the stock is down over 70% since its debut. However, analysts currently suggest the stock could grow over 150% in the next 12 months. It’s the lowest upside on this list of potential multi-bagger penny stocks, but it also is trading for above $2 at this time.  

Harpoon Therapeutics (HARP) 

Stacks of pennies representing penny stocks. Nano-Cap Penny Stocks

Source: John Brueske / Shutterstock.com

Last on this list of penny stocks to watch in 2023 is Harpoon Therapeutics (NASDAQ:HARP). The company is a true penny stock that is currently trading for under a dollar per share. The company is a clinical-stage immune-oncology company. Harpoon is attempting to use the power of T-cells for patients with hard-to-treat tumors.  

As investors in this space know, a key predictor of success is the company’s pipeline. Harpoon Therapeutics has a fairly expansive pipeline. And it is partnering with AbbVie (NYSE:ABBV) to bring its lead candidate, HPN217, through clinical trials. However, HPN271 is only in Phase 1 trials. That means the company is years away from being profitable.  

HARP stock began publicly trading in 2019. It soared to an all-time high of over $22 in 2021 but has plummeted since then. In the last 12 months alone, investors have had to swallow a 69% decline. Nevertheless, analysts give the stock a consensus Moderate Buy rating with the potential for an upside of over 600%. Adding fuel to the analysts’ outlook is institutional ownership which is steady at around 65%.  

Penny Stocks

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More: Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.     

Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.